Corvus Pharmaceuticals, Inc. (CRVS) Earnings Call Transcript & Summary
March 25, 2025
Earnings Call Speaker Segments
Zack Kubow
executiveThanks so much, operator, and good afternoon to all of you. We appreciate you being here for Corvus Pharmaceuticals' conference call covering our business update and financial results for the fourth quarter and the full year 2024. Joining us today to go over the results and business updates are Richard Miller, our Chief Executive Officer, Leiv Lea, our Chief Financial Officer, Jeff Arcara, our Chief Business Officer, and Ben Jones, Senior Vice President of Regulatory and Pharmaceutical Sciences. Our executive team will kick things off with some prepared remarks, and after that we'll move into a question and answer period. I want to remind all of you that the comments management makes today, along with answers to questions, will contain forward-looking statements. Such statements rest on estimates and assumptions as of today, and they carry risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in Corvus's annual report on Form 10-K for the year ended December 31, 2024, which was filed today, as well as other filings the company makes with the SEC from time to time. The company has no obligation to publicly update or revise any forward-looking statements, except as required by law. With that said, I'd like to hand the call over to Leiv Lea. Leiv?
Leiv Lea
executiveThanks, Zack. Pardon me. I'll start with a brief look at how we did in the fourth quarter and across all of 2024 financially, and after that I'll hand things to Richard for an update on the business. R&D spending during Q4 of 2024 came to $5.2 million, versus $3.2 million in the comparable stretch of 2023. That $2 million jump stemmed mostly from greater socalitinib clinical trial costs. For the entire 2024 year, R&D expenses reached $19.4 million, against $16.5 million throughout all of 2023. Across the full 2024 year, the roughly $2.9 million rise was chiefly attributable to larger clinical trial costs tied to socalitinib's development. Our net loss in the fourth quarter of 2024 amounted to $12.1 million, which included a non-cash loss of $2.2 million connected to Angel Pharmaceuticals, our partner in China. We also booked a non-cash loss of $2.3 million stemming from the change in fair value of Corvus' warrant liability in Q4 of 2024; that's against a net loss of $6.7 million in the same quarter of 2023, which had a $1.4 million non-cash loss tied to Angel Pharmaceuticals. For all of 2024, net loss came to $63.3 million, which included a $3.2 million non-cash loss tied to Angel plus a non-cash loss of $33.4 million from the change in fair value of Corvus's warrant liability over the year. That's against a net loss of $27.0 million, which included a $5.3 million non-cash loss tied to Angel, for the whole of 2023. Total stock compensation expense for Q4 and for the full year 2024 was $0.8 million and $3 million, respectively, versus $0.6 million and $2.1 million in those same periods of 2023. At December 31, 2024, Corvus held cash, cash equivalents, and marketable securities of $52 million, compared with $27.1 million as of December 31, 2023; notably, in May 2024, in connection with our financing, we also sold common stock warrants carrying an exercise price of $3.50 that expire on June 30, 2025. During Q4 of 2024, two investors exercised their warrants early, bringing $18.6 million in cash to the company. Should every remaining warrant get exercised, we'd bring in roughly $41 million more in cash. Given our current plans, we expect our cash to provide runway into the first quarter of 2026. Now I'll pass the call to Richard, who will go over our clinical progress and expand on our strategy and plans. Thanks, Leiv, and good afternoon, everyone.
Richard Miller
executiveThanks for spending part of your day with us to hear about where our business stands. As we look toward 2025, we continue to feel very hopeful about socalitinib's potential to become a powerful new treatment choice for many different immune-related conditions, and for cancer too. Socalitinib is a first-in-class oral drug that works by selectively blocking ITK, which lets it regulate and manage parallel signaling pathways in the immune system — that gives it a strong position. Our confidence rests on a growing, substantial collection of evidence drawn from our clinical programs as well as preclinical studies conducted by our own team and by researchers elsewhere. First off, in our Phase 1 study of socalitinib involving patients who had relapsed T-cell lymphoma, we recorded an objective response rate of 39%. That number reflected a complete response rate of 26%, more than double the level typically seen with standard chemotherapies. Armed with these findings, we are now running a registrational Phase 3 study of socalitinib in relapsed peripheral T-cell lymphoma patients, and the substantial experience we've gathered is being put to work across our other socalitinib programs. Turning to interim results from our Phase 1 socalitinib trial in moderate to severe atopic dermatitis patients, the safety and efficacy profile looked favorable; specifically, the socalitinib arms showed meaningful responses versus placebo on the clinically significant endpoints of Investigator Global Assessment (IGA) zero or one and Eczema Area and Severity Index (EASI) 75. Next, there's the preclinical evidence, which suggests that blocking ITK could work in a wide array of indications. These span solid tumors; immune-related conditions like autoimmune lymphoproliferative syndrome, or ALPS, systemic sclerosis, pulmonary fibrosis, and graft-versus-host disease; as well as inflammatory conditions such as asthma, psoriasis, and inflammatory bowel disease. That evidence also sheds light on how the mechanism operates — it shifts differentiation toward TH1 cells, lowers TH2 and TH17 cells together with the cytokines downstream of them, and encourages a transition toward T regulatory cells, which act to dampen inflammation. Because this mechanism can be applied so broadly, we view the promise of ITK inhibition as similar to that of BTK inhibition — a category that people on the Corvus team, myself included, were involved in developing. BTK inhibitors got their initial approval for B-cell malignancies, and after that they were broadened to cover autoimmune conditions. Today I'll go over the data we've already shared in atopic dermatitis and what comes next for that trial, give you some specifics about the NIH study in ALPS that started recently, and walk through the milestones ahead for socalitinib. Back in January, we shared interim results from the Phase 1 study of socalitinib in people who have moderate to severe atopic dermatitis. Four cohorts make up this trial, and each one is enrolling sixteen patients, randomized three-to-one between active and placebo. That's twelve on active, four on placebo. It's a double-blind design, so neither the patient nor the physician knows which they're receiving, and the active drug and placebo are tablets that look and taste the same. Neither the company nor the data review committee is operating under blinded conditions. Patients receive treatment for a span of twenty-eight days, after which we continue monitoring them for an additional thirty days once therapy ends. When you look at atopic dermatitis studies involving other agents at later stages, those typically extend to sixteen weeks or more — so a twenty-eight-day dosing period like ours is relatively short. The main endpoint here is safety and tolerability; for secondary endpoints, we rely on IGA and EASI scores, along with itch measurements reported by patients and biomarkers. In cohort one, socalitinib was administered at one hundred milligrams twice per day, while cohort two received two hundred milligrams once per day. The total drug exposure was identical across those first two cohorts. Based on our lymphoma research, 100 milligrams gets you to 50% target occupancy, whereas 200 milligrams provides about 80% to 100% occupancy. Back in January, we shared results covering 16 patients from cohort one and 10 from cohort two who had finished 28 days of therapy. Putting cohorts one and two together, that came to 19 patients receiving socalitinib and 7 getting placebo. Of the socalitinib group, 26% achieved IGA zero or one, while 37% hit EASI 75. It's worth noting that these endpoints have come to be recognized as markers of clinical benefit and have underpinned the regulatory approval of multiple approved atopic dermatitis therapies. On the placebo side, not a single participant got to an IGA score of zero or one, nor did anyone hit EASI 75. Safety looked clean — nothing concerning turned up, and lab work didn't show any abnormalities that would matter clinically. As for cohort three, where patients take two hundred milligrams twice daily — that's twice the total daily amount given in the previous cohorts — enrollment is nearly wrapped up, and a number of patients have already gotten through the twenty-eight-day follow-up. So far, the efficacy data, which includes everyone in cohorts one and two along with early findings from cohort three, has been favorable and in line with what we've reported before. Nobody receiving active treatment was given topical steroids alongside it or required any rescue medication. One placebo patient did receive concomitant topical corticosteroids; in cohorts one and two, two placebo patients had disease flares during the twenty-eight-day treatment window, while no flares occurred among those on active drug during that same twenty-eight-day period or during follow-up after treatment stopped. Socalitinib has also been very safe so far, with no patient needing to interrupt therapy; we now have experience across more than one hundred lymphoma and atopic dermatitis patients, amounting to over nine thousand patient days of treatment, including lymphoma patients on therapy for as long as two years. We still believe socalitinib works as an active treatment and brings multiple benefits: it's taken by mouth, has a favorable safety profile, and features a novel mechanism of action that leaves room for distinctive positioning, such as possibly serving as a bridge between topical treatments and systemic injectables. We plan to share data from the first three cohorts at the Society of Investigative Dermatology meeting, which runs May 7 to 10 in San Diego. An abstract from us has already been accepted for that meeting, and it will be delivered as both an oral presentation and a poster. Outside of atopic dermatitis, we continue enrolling patients in our registrational Phase 3 trial of socalitinib for those with relapsed PTCL. During a recent T-cell Lymphoma Forum, we presented new data from our Phase 1 study with longer follow-up. Those results demonstrated a median progression-free survival of 6.2 months, a 30% progression-free survival rate at eighteen months, and a median response duration of 17.2 months. Our Phase 3 study's primary endpoint is DFS, which is progression-free survival, and in that trial socalitinib is being compared with belinostat or pralatrexate — the standard of care treatments, which have reported median PFS figures of about three months and eighteen-month PFS rates under 20%. We also recently announced that a Phase 2 trial of socalitinib has started enrolling patients with ALPS, or autoimmune lymphoproliferative syndrome. This study addresses a disease with unmet need, and it will additionally give us more information about how selective ITK inhibition acts in a serious autoimmune disease. People with ALPS are born carrying a genetic mutation in FAST signaling, which leads to lymphoproliferation along with a myriad of autoimmune problems, including anemia, neutropenia, thrombocytopenia, and others. A portion of these patients later go on to develop malignant lymphomas as well.
Richard Miller
executiveWe're conducting the ALPS trial through a clinical research and development agreement with the National Institutes of Allergy and Infectious Diseases at NIH. Up to thirty patients will be enrolled — individuals sixteen years or older whose ALPS has been confirmed by genetic testing. The study uses two dosing cohorts: socalitinib at two hundred milligrams or at four hundred milligrams, given twice daily, for up to 360 days. The primary endpoint is efficacy, which we measure through reductions in spleen and lymph node volumes seen on CT scans. In addition, we'll look at complete blood counts to gauge improvements in cytopenias — that is, lowered blood cell levels. When cytopenias get better, patients' quality of life and general health can improve, and those gains act as a biomarker linked to ALPS disease activity, which includes autoantibody levels that react with red cells, white cells, and/or platelets. The secondary endpoints consist of safety and tolerability. In addition, we intend to run a single-agent socalitinib trial in solid tumors for relapsed renal cell cancer, or RCC, representing a novel immunotherapy strategy for this condition. The study is scheduled to begin in the third quarter of 2025. Aside from socalitinib, we continue to move forward with our other clinical stage development programs. Through ciforadenant, we have been among the leaders in creating adenosine A2A receptor antagonists for treating cancer. One of those is a Phase 1b/2 study we ran together with the Kidney Cancer Research Consortium. In that study, the aim was to see whether ciforadenant could work as an initial treatment option for metastatic renal cell cancer when given alongside ipilimumab and nivolumab. We've now filled all sixty spots across the participating sites, which include MD Anderson, Vanderbilt, Duke, and the University of Pennsylvania. Monitoring of these individuals continues, and sometime later in 2025, we anticipate that our colleagues at the Kidney Cancer Research Consortium will share findings from this study. Last thing worth mentioning: multiple second and third-generation ITK selective inhibitors are moving forward in our pipeline, and these are built to target specific ITK signaling pathways more selectively. Looking ahead to the rest of 2025, our priority stays on pushing forward socalitinib's wide-ranging potential, and we see a number of possible milestones on the horizon. First, in May, at the Society for Investigative Dermatology meeting, we'll share further results from the Phase 1 atopic dermatitis study. Second, complete findings from that Phase 1 atopic dermatitis trial should arrive during the third quarter. Third, we plan to launch a Phase 2 solid tumor study of socalitinib in the third quarter of 2025, and we expect the first data from it in the first half of 2026. Fourth, a Phase 2 atopic dermatitis study is set to begin in late 2025. Fifth, we'll keep opening sites and boosting enrollment in the registration program for socalitinib and PTCL, working toward interim data in late 2026. Based on how many patients end up signing up, there's a chance the first results from the Phase 2 ALPS trial could come out at the end of 2025 or the start of 2026. Our current cash balance will fund us into Q1 of 2026, which gives us room to reach these important milestones and demonstrate more convincingly the value of our programs — particularly the substantial opportunity that comes from inhibiting ITK in both immunology and oncology. We're looking forward to updating everyone on our progress. With that, I'll turn it back to the operator so we can begin the Q&A.
Jeff Jones
analystAfternoon, everyone, and I appreciate you fielding my question. There's a lot of new data on the way, so this is a genuinely thrilling period for all of you. I suppose I'll begin with the AD side and that May update — should we be looking for complete results from cohort three, plus extra subjects from cohort two? And when it comes to the efficacy bar you need to clear, what target do you have in mind for pushing this forward in that Phase 2a you just referenced? Or, put another way, in terms of simply being competitive within this space.
Richard Miller
executiveAll right. Jeff, regarding that May meeting — the Society of Investigative Dermatology — our plan is to present the complete dataset for cohort one along with the complete dataset for cohort two. Enrollment and follow-up for both of those cohorts are already finished. For cohort three, enrollment is nearly wrapped up, and the twenty-eight-day follow-up is now arriving for patients. On top of that, we'll also have an additional one-month follow-up afterward. So complete data will be available across cohorts one, two, and three, and I likewise anticipate having biomarker data covering those initial three cohorts too.
Jeff Jones
analystAll right, that sounds good. Now, regarding the efficacy bar and the success hurdles that you're evaluating?
Richard Miller
executiveSo, to begin with, we're quite happy with the efficacy observed in cohort one and two. Let me remind you that this involves twenty-eight days of treatment. We're seeing roughly a thirty percent difference in some of these, and a twenty-five to thirty-five percent difference between placebo, which was zero in cohort one and two, and our actives — that's a pretty solid figure. And if that figure holds or gets better, that would be, in our view, quite favorable. Naturally, a lot of people wonder what might occur if we extend how long therapy lasts, and that's something we're considering and it will come in time. So we're quite satisfied with the efficacy results we've had so far when it comes to the competitive landscape. Naturally, ours is oral; our mechanism of action is different. Safety has looked really good up to now. As for convenience, the study — the way our study was designed was really meant to figure out whether selective inhibition of ITK played some role in immune diseases. Is there some signal, some hint of efficacy in an autoimmune disease? And I believe we've found that. Naturally, as we consider Phase 2 trials and beyond, we'll start to consider what's needed for registration, and so on. But from a competitive perspective, as far as I know, we're the only selective ITK inhibitor. I'm aware that other companies have ITK inhibitors and are discussing them now, but those aren't selective, and we consider that essential in the biology; so I think we're in pretty good shape on this.
Jeff Jones
analystThanks, Richard. I'll rejoin the line later.
Aydin Huseynov
analystHello there, and good afternoon to all. Richard, nice work on the strides made during this quarter. I have a few things to ask. About the possible cohort four — can you shed some light on what you intend to do there? Are you still planning to use a four hundred milligram dose? Also, could you broadly explain how the dosing differs? In other words, what's the reason for preferring four hundred milligrams, given that in the oncology study your best dose turned out to be only two hundred milligrams?
Richard Miller
executiveI appreciate that, Aydin. That's a solid question. To give everyone the full picture: the first cohort received 100 mg twice daily, while the second got the identical daily total—200 mg as a single dose. For cohort three, participants took 200 mg two times per day. Cohort four, as you mentioned, would deliver 400 mg once, keeping that same total. Now, before we commit to running cohort four—which is indeed our intention—we need to review the complete data set from cohort three. Cohorts one and two are already in hand. Once we've examined cohort three's results, we'll make the call on whether to proceed. At this moment, our intention is to proceed with that approach, though we're also evaluating alternatives—such as lengthening how long patients receive treatment. As you're aware, all of the dosage levels—one hundred, two hundred, and four hundred—achieve excellent receptor occupancy; and naturally, as I've mentioned on earlier calls, we still lack clarity regarding what is required to produce a clinical or biologic response in atopic dermatitis, and whether full occupancy is truly necessary. Yet even with our initial dose of one hundred, occupancy is quite strong. So for the time being, we intend to move forward with cohort four. However, prior to making a final commitment to that, we'd like to review our data.
Aydin Huseynov
analystThat's clear. Now, about the treatments they'd received before — I'm aware a lot of those individuals had already not responded to DUPIXENT. The first 2 cohorts. What about cohort 3, though? Did you observe those patients — pardon me. Pardon me. They haven't had DUPIXENT, my mistake, that's cohort 1. So would cohort 3 likewise be largely made up of patients who are DUPIXENT naive?
Richard Miller
executiveIn cohort 3, we intentionally looked for patients who were more ill. As a result, cohort 3 does include a greater number of failures on DUPIXENT as well as on systemic treatment. Also, up to this point — obviously the cohort isn't finished — our baseline EASI scores do seem to be higher; we'll need to examine that, and we'll find out how, you know, how it plays out. As for whether there's a, you know, whether there's a notably strong or beneficial outcome among the DUPIXENT failures, that remains unknown to us. How exactly that factor plays a role is still not something we really understand.
Aydin Huseynov
analystAll right, got it. Then the final item is about biomarkers. I believe you said that in May you'll be discussing biomarkers. Could you go into a bit more detail on that? For atopic dermatitis, which biomarkers exist?
Richard Miller
executiveSure, I'd say certain findings we shared in January or in December regarding biomarkers are now being verified through the studies we're currently running. On top of that, we've identified a few additional things that strike me as pretty compelling. As you know, I've mentioned—we've been discussing and examining these T regulatory suppressor cells along with other cells, and in my view they're proving to be really fascinating. Among patients who get the drug, we keep observing a highly lasting impact from our treatment. And yes, the dataset is small, and it's quite early, yet at this stage it's also quite thought-provoking.
Aydin Huseynov
analystOkay, got it. Many thanks.
Graig Suvannavejh
analystHi there, this is Sam sitting in for Graig. Appreciate you taking our questions. Perhaps one about ALPS, since this is a fresh indication. Could you tell us, regarding the addressable patient population, what your due diligence shows, and also whether, among individuals with ALPS, there might be a subset who would make ideal candidates for socalitinib? Thank you.
Richard Miller
executiveAll right. In the US, ALPS, or ALTS, autoimmune lymphoproliferative syndrome, is a genetic condition. You are born with it. Let me provide a bit of background about this disease. Infants arrive with it. Around the age of two, they begin developing anemia and dysplains and lymphadenopathy. Infections occur, and naturally a diagnosis gets made. After that they remain on lifelong immunosuppressive treatments — chemo cyclophosphamide, steroids, mTOR inhibitors, that sort of thing — and they may stay on those for a long period. This disease cannot be cured, and they will experience adenopathy and cytopenias that wax and wane — anemia, neutropenia, thrombocytopenia. It is now possible for them to live thirty, forty, fifty years. Yet they endure many of the complications. They develop massive splenomegaly. That is another issue they face, which occasionally can rupture. Among these patients, a subset — perhaps ten, twenty percent — eventually develop malignant lymphomas. Typically these are B-cell lymphomas. However, the abnormal cell in ALPS is a T-cell. It is an abnormal T-cell. Termed the double negative T-cell; it lacks CD8 or CD4. I will not delve into its biology, but it carries a great deal of ITK expression. In our research examining how socalitinib acts in various murine autoimmune models, we discovered that the same — there is a mouse strain known as the MRLLPR negative negative mouse that carries the identical mutation found in these patients. Genetically speaking, essentially the same disease. And when our drug was given to these animals, it proved dramatically effective. Truly dramatically effective. Cytopenias reverse and return to normal, splenomegaly, lymphopenia, all of that. Essentially, these animals return to normal. That is what pushed us to say hey. Let us go treat the human genetic, you know, identical genetic disease in humans. That brought us to the NIAID, which holds a very large collection of these patients; these days most pediatric hospitals have patients like this, and you asked about the market. In the United States there are roughly two thousand five hundred patients with this disease. At present. They survive a long time. As I mentioned, they reach age forty fifty, some die sooner. But by and large that is their lifespan. To our current knowledge, I do not believe there is any particular subset that would be more or less amenable to this therapy. So I just, you know, we simply do not know. Occasionally patients have slightly different mutations. Yet the core issue, whether in mice or in people, is that their cells—their lymphocytes—fail to undergo apoptosis. There's a remarkably strong link, you know, between signaling through the T-cell receptor and apoptosis. Just think about it: when antigen shows up or an infection is present, you want your T-cells to multiply and wipe out that infection, but afterward, once the infection has been cleared, you want those T-cells to disappear. Apoptosis is what makes that happen. ITK controls that process. ITK plays numerous roles across different signaling pathways. And if you inhibit ITK, apoptosis gets restored in these cells; that's the basis for this approach. So essentially, this is a therapy that, in my view, you'd be on for an extended period; and, you know, based on the safety profile observed thus far, I believe it could matter a great deal. Also, from the regulatory angle, I don't think this is a condition where you'll be required to run large randomized clinical trials; so that's another point worth considering. We're quite enthusiastic and intrigued by this condition. My lengthy response probably makes that clear. And lastly, what this allows is—I mean, it's truly a chance to examine how our drug affects every kind of autoimmune manifestation. Antibodies against red cells, antibodies against platelets, all of that. Which we believe will carry significant relevance for other autoimmune conditions. Does that address what you asked? Most likely.
Graig Suvannavejh
analystAbsolutely. That's really helpful. Thank you very much, Richard, for fielding our question.
Roger Song
analystHello. Cha Cha Yang here, standing in for Roger. I'm looking ahead to your phase two trial for AD, and I'd like to know if you could shed some light on which subpopulations within the disease you intend to target. To be more specific, could you address things such as prior medication use, baseline EASI scores, and any demographic insights? That would be wonderful.
Richard Miller
executiveThat's a fairly difficult question, given that Phase one isn't complete yet, but moderate to severe atopic dermatitis that has failed topical corticosteroids, or systemic therapy. Quite similar to the criteria we're employing at present. Not sure whether I'd require — I mean, baseline EASI scores need to be moderate, which is sixteen or higher. So I doubt we'd have any requirements past that. You know, I believe a typical study would examine two different dose levels plus a placebo. So likely a three-arm study of perhaps around two hundred patients in total; but, you know, that's an — you know, sort of an approximate answer right now. But all of that is fairly standard. Okay. That sounds fine; and the endpoint would be either EASI 75 — those who reach EASI-seventy-five. Or IGA zero one. That's a pretty standard endpoint these days.
Li Watsek
analystHey there, everyone; Daniel Bronder here, filling in for Li. I'd like to ask about how you're ranking the opportunities for socalitinib in oncology against inflammatory disease, and how that thinking evolves as you head into later-stage trials.
Richard Miller
executiveAll right. So at this moment, socalitinib is in a phase three registration trial, and data from that could come in under two years. That means we're pressing forward on every front as hard as possible. The thinking, the plan, is to secure an approval in lymphoma. To secure an approval in an immune disease as well; we do understand there are certain concerns around using one similar same drug for both autoimmune conditions and cancer. We've got a highly aggressive effort underway with second and third-generation compounds; beyond that, we believe dosing and duration will end up being quite distinct between oncology and immunology. Take Rituxan as a strong illustration, which originated in my lab at IDAC. Rituxan holds approval for lymphomas, as you're aware. It also holds approval for rheumatoid arthritis, pemphigus, ITP, and likely several additional autoimmune diseases. And pricing isn't really an issue at all, since the treatment regimens mean that measured per milligram, it ends up being fairly comparable; so the plan at present is to drive ahead on all of these fronts and, you know, go deeper and deeper into the pipeline and, you know, at some stage, naturally, we understand that autoimmune diseases represent a vast undertaking. There are many different diseases and competitive areas, and naturally, when the time is right, we'd look at some sort of a collaboration or partnership.
Daniel Bronder
analystAll right. Thanks a lot for such a thorough response. And the other thing we were curious about is something you touched on a bit earlier. When it comes to cohort four being presented later, is that mostly because you're holding off until you see how cohort three turns out, or has enrollment been slower in a broader sense?
Richard Miller
executiveEnrollment hasn't been delayed at all. What we're doing is waiting on the results from cohort three. Then we'll decide whether to move forward with cohort or possibly grow one of the remaining cohorts.
Daniel Bronder
analystAll right. Great. Thanks a lot.
Jiale Song
analystHello there. Good afternoon, and I appreciate you answering my question. I've got just a single one regarding the solid tumor trial that is being planned. Are there particular indications you believe fit socalitinib best, or is this going to be a broad basket study? And secondly, is another dose escalation required, or could we begin at the PTCL dose? Thank you.
Richard Miller
executiveRegarding the first portion — which tumors? My preference would be to begin with the immune responses tumors. Which ones are those? Renal cell cancer. Lung cancer would work well. Given that you're targeting tumors where you think there's already some sign of immunotherapy working, those would probably be the first ones to go after. Melanoma might be a possibility too, but it's much rarer, and existing therapies, you know, do a fairly decent job with it. So I'd mention renal and lung. A dose escalation isn't something I see as required, though trying out various doses is definitely something you'd want to do. Testing different dose levels would be valuable — not the kind of traditional dose escalation you'd picture in a phase one oncology trial. Still, you'd likely want to look at a range of doses. Even so, at this point we've got a solid grasp on the dosing, and there's a really reliable pharmacodynamic readout in place — we understand the level needed to fully occupy the ITK target. So whether it's one hundred, two hundred, three hundred, or four hundred, the numbers land in roughly the same range. Each of them will produce more or less equivalent results.
Jiale Song
analystGreat. Thanks for that.
Richard Miller
executiveThank you.
Richard Miller
executiveAll right, I appreciate each of you joining this call, and we're eager to share further updates down the road. Many thanks.
Operator
operatorAppreciate it. That brings an end to what we had scheduled for today. Thanks for joining us. Everyone is free to drop off now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Corvus Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Corvus Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Corvus Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.